<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39394536</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-3289</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>11</Day></PubDate></JournalIssue><Title>Administration and policy in mental health</Title><ISOAbbreviation>Adm Policy Ment Health</ISOAbbreviation></Journal><ArticleTitle>Changes in Antipsychotic Medication Adherence Among Medicaid Beneficiaries with Schizophrenia During COVID-19.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10488-024-01416-9</ELocationID><Abstract><AbstractText>To identify patterns of medication adherence during the pandemic and factors associated with these patterns among Medicaid-enrolled individuals with schizophrenia who had highly adherent medication use prior to the COVID-19 pandemic. We used Medicaid claims from Philadelphia to identify individuals with schizophrenia ≥ 18 years of age, their demographic characteristics, and health service use. We used group trajectory models to identify adherence trends, and ANOVA to examine associations between adherence groups and demographic characteristics and service use. The sample included 1,622 individuals. A 4-group trajectory model best fit our data. Seventy percent of individuals averaged about 92% adherence throughout the study period; 10% experienced a pronounced decline when the pandemic started (pandemic non-adherers); 11% experienced a sharp decline mid-pandemic (late non-adherers); and 9% experienced a sharp decline at the beginning of the pandemic and returned to higher adherence after a year (disrupted adherers). Adherers were least likely to be diagnosed with a substance use disorder, and had more telehealth visits, mental health outpatient visits, and fewer emergency department visits on average. Late non-adherers were more likely than adherers to have substance use disorders and physical health conditions. Pandemic non-adherers had more co-occurring psychiatric disorders than adherers and had the lowest use of case management. Three in ten previously adherent individuals with schizophrenia became less adherent to antipsychotic medications, either at the onset or later in the pandemic. Our findings point to telehealth and case management as critical strategies for treatment engagement, especially during public health crises, and well as the need to address co-occurring conditions.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Siyuan</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-1882-2304</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, 3535 Market St, 3rd Floor, Philadelphia, PA, 19104, USA. Lisa.Shen@pennmedicine.upenn.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, 3535 Market St, 3rd Floor, Philadelphia, PA, 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Candon</LastName><ForeName>Molly</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-8312-951X</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, 3535 Market St, 3rd Floor, Philadelphia, PA, 19104, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Health Care Management, Wharton School, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lorenc</LastName><ForeName>Emily</ForeName><Initials>E</Initials><Identifier Source="ORCID">0009-0008-4710-0005</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, 3535 Market St, 3rd Floor, Philadelphia, PA, 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jang</LastName><ForeName>Min</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-1661-2242</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, 3535 Market St, 3rd Floor, Philadelphia, PA, 19104, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mandell</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, 3535 Market St, 3rd Floor, Philadelphia, PA, 19104, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Adm Policy Ment Health</MedlineTA><NlmUniqueID>8914574</NlmUniqueID><ISSNLinking>0894-587X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID pandemic</Keyword><Keyword MajorTopicYN="N">Medication adherence</Keyword><Keyword MajorTopicYN="N">Schizophrenia</Keyword><Keyword MajorTopicYN="N">Telehealth</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>12</Day><Hour>9</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>12</Day><Hour>9</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>23</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39394536</ArticleId><ArticleId IdType="doi">10.1007/s10488-024-01416-9</ArticleId><ArticleId IdType="pii">10.1007/s10488-024-01416-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>A SAS procedure based on mixture models for estimating developmental trajectories: Bobby L. Jones, Daniel S. Nagin, Kathryn Roeder, 2001. Accessed August 2, 2023. https://journals.sagepub.com/doi/ https://doi.org/10.1177/0049124101029003005</Citation></Reference><Reference><Citation>Alhazami, M., Pontinha, V. M., Patterson, J. A., &amp; Holdford, D. A. (2020). Medication adherence trajectories: a systematic literature review. Journal of Managed Care and Specialty Pharmacy, 26(9), 1138–1152. https://doi.org/10.18553/jmcp.2020.26.9.1138</Citation><ArticleIdList><ArticleId IdType="doi">10.18553/jmcp.2020.26.9.1138</ArticleId></ArticleIdList></Reference><Reference><Citation>Bareis, N., Tepper, M. C., Wang, R., et al. (2023). Engagement of individuals with serious mental illness in outpatient mental health services and telehealth use during the COVID-19 pandemic. Psychiatry Research. https://doi.org/10.1016/j.psychres.2023.115497</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psychres.2023.115497</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodén, R., Brandt, L., Kieler, H., Andersen, M., &amp; Reutfors, J. (2011). Early non-adherence to medication and other risk factors for rehospitalization in schizophrenia and schizoaffective disorder. Schizophrenia Research, 133(1–3), 36–41. https://doi.org/10.1016/j.schres.2011.08.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.schres.2011.08.024</ArticleId></ArticleIdList></Reference><Reference><Citation>Busch, A. B., Huskamp, H. A., Raja, P., Rose, S., &amp; Mehrotra, A. (2022). Disruptions in care for Medicare beneficiaries with severe mental illness during the COVID-19 pandemic. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2021.45677</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.45677</ArticleId></ArticleIdList></Reference><Reference><Citation>Byerly, M. J., Thompson, A., Carmody, T., et al. (2007). Validity of electronically monitored medication adherence and conventional adherence measures in schizophrenia. Psychiatric Services (Washington, DC), 58(6), 844–847. https://doi.org/10.1176/ps.2007.58.6.844</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/ps.2007.58.6.844</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantor, J. H., McBain, R. K., Kofner, A., Stein, B. D., &amp; Yu, H. (2021). Availability of outpatient telemental health services in the United States at the outset of the COVID-19 pandemic. Medical Care, 59(4), 319–323. https://doi.org/10.1097/MLR.0000000000001512</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MLR.0000000000001512</ArticleId></ArticleIdList></Reference><Reference><Citation>Capasso, A., Jones, A. M., Ali, S. H., Foreman, J., Tozan, Y., &amp; Di Clemente, R. J. (2021). Increased alcohol use during the COVID-19 pandemic: The effect of mental health and age in a cross-sectional sample of social media users in the US. Preventive Medicine. https://doi.org/10.1016/j.ypmed.2021.106422</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ypmed.2021.106422</ArticleId></ArticleIdList></Reference><Reference><Citation>Chacon, N. C., Walia, N., Allen, A., et al. (2021). Substance use during COVID-19 pandemic: impact on the underserved communities. Discoveries, 9(4), e141.</Citation><ArticleIdList><ArticleId IdType="doi">10.15190/d.2021.20</ArticleId></ArticleIdList></Reference><Reference><Citation>Civan Kahve, A., Kaya, H., Darben, Y., Gul Cakil, A., &amp; Goka, E. (2021). From predictions to evidence: treatment compliance, disease progression and social compliance of patients with schizophrenia in the COVID-19 pandemic. Perspectives in Psychiatric Care, 57(4), 1991–1998. https://doi.org/10.1111/ppc.12824</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ppc.12824</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical Classifications Software (CCS) for ICD-10-PCS (beta version). Accessed August 2, 2023. https://hcup-us.ahrq.gov/toolssoftware/ccs10/ccs10.jsp</Citation></Reference><Reference><Citation>Creedon, T. B., Schrader, K. E., O’Brien, P. L., Lin, J. R., Carroll, C. D., &amp; Mulvaney-Day, N. (2020). Rural-nonrural differences in telemedicine use for mental and substance use disorders among Medicaid beneficiaries. Psychiatric Services (Washington, D. C.), 71(8), 756–764. https://doi.org/10.1176/appi.ps.201900444</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ps.201900444</ArticleId></ArticleIdList></Reference><Reference><Citation>Elixhauser Comorbidity Software Refined for ICD-10-CM. Accessed August 2, 2023. https://hcup-us.ahrq.gov/toolssoftware/comorbidityicd10/comorbidity_icd10.jsp</Citation></Reference><Reference><Citation>2023 Exceptional Surveillance of Psychosis and Schizophrenia in Children, Young People and Adults (NICE Guidelines CG155 and CG178). National Institute for Health and Care Excellence (NICE); 2023. Accessed June 10, 2024. http://www.ncbi.nlm.nih.gov/books/NBK597541/</Citation></Reference><Reference><Citation>Franklin, J. M., Shrank, W. H., Pakes, J., et al. (2013). Group-based trajectory models: a new approach to classifying and predicting long-term medication adherence. Medical Care, 51(9), 789. https://doi.org/10.1097/MLR.0b013e3182984c1f</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MLR.0b013e3182984c1f</ArticleId></ArticleIdList></Reference><Reference><Citation>Grossman, E. R., Benjamin-Neelon, S. E., &amp; Sonnenschein, S. (2020). Alcohol Consumption during the COVID-19 Pandemic: a Cross-Sectional Survey of US Adults. International Journal of Environmental Research and Public Health, 17(24), 9189. https://doi.org/10.3390/ijerph17249189</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph17249189</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickson, R. P., Annis, I. E., Killeya-Jones, L. A., &amp; Fang, G. (2020). Opening the black box of the group-based trajectory modeling process to analyze medication adherence patterns: an example using real-world statin adherence data. Pharmacoepidemiology and Drug Safety, 29(3), 357–362. https://doi.org/10.1002/pds.4917</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.4917</ArticleId></ArticleIdList></Reference><Reference><Citation>Keepers, G. A., Fochtmann, L. J., Anzia, J. M., et al. (2020). The American psychiatric association practice guideline for the treatment of patients with Schizophrenia. American Journal of Psychiatry, 177(9), 868–872. https://doi.org/10.1176/appi.ajp.2020.177901</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajp.2020.177901</ArticleId></ArticleIdList></Reference><Reference><Citation>Korhonen, M. J., Ruokoniemi, P., Ilomäki, J., Meretoja, A., Helin-Salmivaara, A., &amp; Huupponen, R. (2016). Adherence to statin therapy and the incidence of ischemic stroke in patients with diabetes. Pharmacoepidemiology and Drug Safety, 25, 161–169. https://doi.org/10.1002/pds.3936</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.3936</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo-Ciganic, W. H., Donohue, J. M., Jones, B. L., et al. (2016). Trajectories of diabetes medication adherence and hospitalization risk: a retrospective cohort study in a large state Medicaid program. Journal of General Internal Medicine, 31, 1052–1060. https://doi.org/10.1007/s11606-016-3747-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11606-016-3747-6</ArticleId></ArticleIdList></Reference><Reference><Citation>MacEwan, J. P., Forma, F. M., Shafrin, J., Hatch, A., Lakdawalla, D. N., &amp; Lindenmayer, J. P. (2016). Patterns of adherence to oral atypical antipsychotics among patients diagnosed with schizophrenia. Journal of Managed Care and Specialty Pharmacy, 22(11), 1349–1361. https://doi.org/10.18553/jmcp.2016.22.11.1349</Citation><ArticleIdList><ArticleId IdType="doi">10.18553/jmcp.2016.22.11.1349</ArticleId></ArticleIdList></Reference><Reference><Citation>Muruganandam, P., Neelamegam, S., Menon, V., Alexander, J., &amp; Chaturvedi, S. K. (2020). COVID-19 and Severe Mental Illness: Impact on patients and its relation with their awareness about COVID-19. Psychiatry Research. https://doi.org/10.1016/j.psychres.2020.113265</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psychres.2020.113265</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagin, D. S., &amp; Odgers, C. L. (2010). Group-based trajectory modeling in clinical research. Annual Review of Clinical Psychology, 6(1), 109–138. https://doi.org/10.1146/annurev.clinpsy.121208.131413</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.clinpsy.121208.131413</ArticleId></ArticleIdList></Reference><Reference><Citation>Novick, D., Haro, J. M., Suarez, D., Perez, V., Dittmann, R. W., &amp; Haddad, P. M. (2010). Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Research, 176(2–3), 109–113. https://doi.org/10.1016/j.psychres.2009.05.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psychres.2009.05.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Pringsheim, T., Kelly, M., Urness, D., Teehan, M., Ismail, Z., &amp; Gardner, D. (2017). Physical health and drug safety in individuals with Schizophrenia. Can J Psychiatry Rev Can Psychiatr., 62(9), 673–683. https://doi.org/10.1177/0706743717719898</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0706743717719898</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruksakulpiwat S, Zhou W, Niyomyart A, Wang T, Kudlowitz A. How does the COVID-19 pandemic impact medication adherence of patients with chronic disease?: A systematic review. Chronic Illn. Published online August 16, 2022:17423953221110151. https://doi.org/10.1177/17423953221110151</Citation></Reference><Reference><Citation>Schulze, L. N., Stentzel, U., Leipert, J., et al. (2019). Improving medication adherence with telemedicine for adults with severe mental illness. Psychiatric Services (Washington, DC), 70(3), 225–228. https://doi.org/10.1176/appi.ps.201800286</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ps.201800286</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon, E., Edwards, A. M., Sajatovic, M., Jain, N., Montoya, J. L., &amp; Levin, J. B. (2022). Systematic literature review of text messaging interventions to promote medication adherence among people with serious mental illness. Psychiatric Services (Washington, DC), 73(10), 1153–1164. https://doi.org/10.1176/appi.ps.202100634</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ps.202100634</ArticleId></ArticleIdList></Reference><Reference><Citation>Strauss, G. P., Macdonald, K. I., Ruiz, I., Raugh, I. M., Bartolomeo, L. A., &amp; James, S. H. (2022). The impact of the COVID-19 pandemic on negative symptoms in individuals at clinical high-risk for psychosis and outpatients with chronic schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 272(1), 17–27. https://doi.org/10.1007/s00406-021-01260-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00406-021-01260-0</ArticleId></ArticleIdList></Reference><Reference><Citation>The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic criteria for research. Accessed August 2, 2023. https://www.who.int/publications-detail-redirect/9241544554</Citation></Reference><Reference><Citation>Tiihonen, J., Tanskanen, A., &amp; Taipale, H. (2018). 20-year nationwide follow-up study on discontinuation of antipsychotic treatment in first-episode Schizophrenia. American Journal of Psychiatry, 175(8), 765–773. https://doi.org/10.1176/appi.ajp.2018.17091001</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajp.2018.17091001</ArticleId></ArticleIdList></Reference><Reference><Citation>Twisk, J., &amp; Hoekstra, T. (2012). Classifying developmental trajectories over time should be done with great caution: a comparison between methods. Journal of Clinical Epidemiology, 65(10), 1078–1087. https://doi.org/10.1016/j.jclinepi.2012.04.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2012.04.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Valenstein, M., Copeland, L. A., Blow, F. C., McCarthy, J. F., Zeber, J. E., Gillon, L., Bingham, C. R., &amp; Stavenger, T. (2002). Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Medical Care., 40(8), 630–639.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005650-200208000-00002</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Yao F, Wang H, Wang C, Guo Z. Medication Adherence and Influencing Factors Among Patients With Severe Mental Disorders in Low-Income Families During COVID-19 Outbreak. Front Psychiatry. 2022;12. Accessed August 2, 2023. https://www.frontiersin.org/articles/ https://doi.org/10.3389/fpsyt.2021.799270</Citation></Reference><Reference><Citation>White, H. R., Stevens, A. K., Hayes, K., &amp; Jackson, K. M. (2020). Changes in alcohol consumption among college students due to COVID-19: effects of campus closure and residential change. Journal of Studies on Alcohol and Drugs, 81(6), 725–730. https://doi.org/10.15288/jsad.2020.81.725</Citation><ArticleIdList><ArticleId IdType="doi">10.15288/jsad.2020.81.725</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock, A. D., Huskamp, H. A., Busch, A. B., et al. (2023). Use of telemedicine and quality of care among Medicare enrollees with serious mental illness. JAMA Health Forum. https://doi.org/10.1001/jamahealthforum.2023.3648</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamahealthforum.2023.3648</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodall, A. A., Abuzour, A. S., Wilson, S. A., et al. (2024). Management of antipsychotics in primary care: insights from healthcare professionals and policy makers in the United Kingdom. PLoS ONE. https://doi.org/10.1371/journal.pone.0294974</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0294974</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao, L., Liu, H., &amp; Tian, X. (2022). Medication adherence among community-dwelling schizophrenia patients during the COVID-19 pandemic: a cross-sectional study. Psychiatry Research. https://doi.org/10.1016/j.psychres.2022.114841</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psychres.2022.114841</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu, J. M., Myers, R., McConnell, K. J., Levander, X., &amp; Lin, S. C. (2022). Trends in outpatient mental health services use before and during the COVID-19 pandemic. Health Aff (Millwood)., 41(4), 573–580. https://doi.org/10.1377/hlthaff.2021.01297</Citation><ArticleIdList><ArticleId IdType="doi">10.1377/hlthaff.2021.01297</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>